Navigation Links
HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology

SAN DIEGO, Nov. 8, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Shenzhen Polytechnic School of Applied Chemistry and Biotechnology (SPSACBT). The alliance with HUYA will assist the school in accelerating the development of novel drugs, discovered from research laboratories within the school, to international standards.

The agreement provides HUYA with access to and first review of certain novel therapeutic candidates owned or controlled by SPSACBT.  Correspondingly, the school gains access to HUYA's expertise in drug development as well as its global network of pharmaceutical partners.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing innovative compounds from the country, utilizing its expertise to advance these compounds for global markets.

Shenzhen Polytechnic School of Applied Chemistry and Biotechnology is part of Shenzhen Polytechnic located in Shenzhen. The school has a strong research focus with distinguished professors and scientists. In the recent years, it has undertaken three major projects funded by the National Natural Science Foundation and greater than 80 research projects funded by provincial and local government.  It has established long-term collaborations with several overseas universities, as well as enterprises and companies in related industries.

"Shenzhen Polytechnic School of Applied Chemistry and Biotechnology is recognized for its strong research capabilities," said Clement Gingras, HUYA's CTO and COO, China. "We believe that the alliance between HUYA and the school will help enhance product opportunities from China's biopharmaceutical industry."

Professor Junsong Zhang, President of Shenzhen Polytechnic School of Applied Chemistry and Biotechnology, commented, "We aim to become a world-class university with superior vocational technology to contribute to China's development of the pharmaceutical sciences industry, we are optimistic, that with HUYA's assistance, we will advance in that direction and reach our goal."


HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at


The School of Applied Chemistry and Biotechnology was established in January 2005. As part of Shenzhen Polytechnic, the school consists of eight specialties: Fine Chemicals Manufacturing Technology, Chemical Analytical Technology, Polymer Material Processing Engineering, Food Biotechnology, Food Nutrition and Inspection, Pharmacy, Drug Management, and Urban Landscape, and three research centers: the Center of Biology Application Engineering Technology, the Center of Landscape Planning and Designing, and the Center of Food Safety Assessment and Research. Situated at Shenzhen, Guangdong Province, China, the School of Applied Chemistry and Biotechnology extends over an area of 6000 square meters with well-equipped workshops and laboratories. The school has a total funding of 7.3 million Yuan (US $1.1 million) and accepted about 157 grant-funded research programs and 80 research projects; these projects have yielded 34 technological exhibits in the China Hi-Tech Fair (CHTF). For more information, please visit  


Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International

Ping Yang, MS
Business Development Manager
HUYA Bioscience International

SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Protect Marylands Bioscience Industry
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... today announced that Google has adopted the Synaptics ® ... controller solutions to power its newest flagship smartphones, the ... Huawei. --> --> ... Google to provide strategic collaboration in the joint development ...
Breaking Biology News(10 mins):